文献速递免疫规划妇幼与学校卫生

围孕期接种灭活COVID-19疫苗:对孕妇和新生儿安全性的评估

Inactivated COVID-19 vaccines in peri-pregnancy period: Evaluation of safety for both pregnant women and neonates.
PubMed 文献 · Vaccine · 2023-11-10

这项在中国开展的前瞻性观察性队列研究纳入2021年1月1日至2021年12月31日期间接受孕期保健的孕妇,按围孕期是否接种灭活COVID-19疫苗分为疫苗组(n=60)和对照组(n=60)。主要结局为孕妇胎膜早破(PROM)和新生儿不良事件(包括引产/死亡、早产、低出生体重和新生儿重症监护病房(NICU)入住)的发生率。结果显示两组PROM和新生儿不良事件无显著差异;仅孕早期血清丙氨酸转氨酶(ALT)在疫苗组显著更高。作者结论为围孕期接种灭活COVID-19疫苗对孕妇和新生儿安全,并建议监测孕早期ALT水平。

要点

  • 疫苗组与对照组胎膜早破发生率无显著差异(25.42% vs 19.67%,p=0.438)。
  • 两组新生儿不良事件发生率无显著差异(11.86% vs 4.92%,p=0.148)。
  • 仅孕早期血清ALT在疫苗组显著更高(20.67 ± 20.34 vs 13.05 ± 9.43;RR: 5.38;p = 0.04)。

核心结论

  • 敏感性分析表明结果稳健,因此可认为围孕期接种灭活COVID-19疫苗对孕妇和新生儿安全,无论接种时间及用药情况。
  • 此外,建议在整个孕早期监测ALT水平。

研究设计与样本

  • 前瞻性观察性队列研究,纳入2021年1月1日至2021年12月31日期间接受孕期保健的孕妇。
  • 孕妇按围孕期是否接种灭活COVID-19疫苗分为疫苗组(n = 60)和对照组(n = 60)。
  • 主要结局为孕妇胎膜早破(PROM)和新生儿不良事件(包括引产/死亡、早产、低出生体重和新生儿重症监护病房(NICU)入住)的发生率,以及若干孕妇和新生儿相关的次要结局。
  • 采用逆概率治疗加权(IPTW)调整基线协变量,并在IPTW后建立线性和逻辑回归模型分别分析连续和二元结局。
  • 敏感性分析计算E值,并进行倾向性评分匹配分析和多因素回归分析以证明IPTW结果的稳健性;此外进行接种时间亚组分析和用药亚组分析。

主要发现

  • 120名新生儿中,疫苗组与对照组胎膜早破发生率无显著差异(25.42% vs 19.67%,p = 0.438)。
  • 疫苗组与对照组新生儿不良事件发生率无显著差异(11.86% vs 4.92%,p = 0.148)。
  • 次要结局中仅孕早期血清丙氨酸转氨酶(ALT)在两组间有统计学显著差异,孕早期疫苗组ALT水平显著更高(20.67 ± 20.34 vs 13.05 ± 9.43;RR: 5.38;p = 0.04)。
  • 敏感性分析中,主要结局PROM和新生儿不良事件的E值分别为2.04和5.00。
  • 倾向性评分匹配分析和多因素回归分析得出相同结论;主要结局结果在接种时间亚组和用药亚组中均一致。

关键数值与推荐

  • 疫苗组胎膜早破发生率25.42% vs 对照组19.67%(p = 0.438),无显著差异。
  • 疫苗组新生儿不良事件发生率11.86% vs 对照组4.92%(p = 0.148),无显著差异。
  • 孕早期血清ALT:疫苗组20.67 ± 20.34 vs 对照组13.05 ± 9.43;RR: 5.38;p = 0.04,疫苗组显著更高。
  • 主要结局PROM和新生儿不良事件的E值分别为2.04和5.00。

临床怎么用

  • 作者结论认为围孕期接种灭活COVID-19疫苗对孕妇和新生儿安全,无论接种时间及用药情况。
  • 作者建议在整个孕早期监测ALT水平。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pregnant women have been excluded from vaccination of COVID-19 due to the lack of strong clinical evidence, which may place pregnant women at greater risk of contracting COVID-19. We conducted this study in China to investigate the maternal and neonatal safety of inactivated COVID-19 vaccination administered during the peri-pregnancy period. METHODS: This prospective observational cohort study enrolled pregnant women who received pregnancy care between January 1, 2021, and December 31, 2021. Pregnant women were categorized into vaccine group (n = 60) and control group (n = 60) based on whether they had received an inactivated COVID-19 vaccine within peri-pregnancy period. The primary outcomes were the incidence of maternal premature rupture of membranes (PROM) and neonatal adverse events, including induced labor/death, premature birth, low birth weight, and neonatal intensive care unit (NICU) admission and several secondary outcomes related to pregnant women and neonates. Inverse probability treatment weighting (IPTW) was employed to adjust for baseline covariates. Linear and logistic regression models were established after IPTW for continuous and binary outcomes, respectively. In sensitivity analysis, E-values were calculated and propensity score matching analysis and multivariate regression analysis used to demonstrate the robustness of IPTW results. Moreover, vaccination time subgroup analysis and medication subgroup analysis were conducted. RESULTS: Out of 120 neonates delivered, there was no significant difference in PROM (25.42 % vs. 19.67 %, p = 0.438) or neonatal adverse events (11.86 % vs. 4.92 %, p = 0.148) between the vaccine and control groups. Moreover, among the secondary outcomes only serum alanine transaminase (ALT) at first trimester had a statistically significant difference between the groups, ALT levels were significantly higher in the vaccine group during the first trimester (20.67 ± 20.34 vs. 13.05 ± 9.43; RR: 5.38; p = 0.04). In sensitivity analysis, the E-values calculated for the primary outcomes PROM and neonatal adverse events are 2.04 and 5.00 respectively. PSM analysis and multivariate regression analysis reached the same conclusion. The results of primary outcomes are both consistent across the vaccination time subgroup and medication subgroup. CONCLUSION: The sensitivity analysis illustrates the robustness of our results, so we can conclude that the vaccination of inactivated COVID-19 vaccine during the peri-pregnancy period is safe for both the pregnant woman and neonates no matter what time of vaccination and the use of medication. In addition, it is recommended to monitor ALT levels throughout the first trimester of pregnancy.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Yang C, Zheng Z, Zheng P, et al. Inactivated COVID-19 vaccines in peri-pregnancy period: Evaluation of safety for both pregnant women and neonates. Vaccine. 2023. PMID: 37949755. doi:10.1016/j.vaccine.2023.11.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。